Savara, Inc. (SVRA)
5.37
0.00 (0.00%)
USD |
NASDAQ |
Sep 04, 16:00
5.39
+0.02
(+0.37%)
After-Hours: 20:00
Savara Research and Development Expense (Quarterly) : 21.95M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 21.95M |
| March 31, 2026 | 23.40M |
| December 31, 2025 | 20.90M |
| September 30, 2025 | 20.59M |
| June 30, 2025 | 20.75M |
| March 31, 2025 | 19.16M |
| December 31, 2024 | 23.29M |
| September 30, 2024 | 20.31M |
| June 30, 2024 | 17.62M |
| March 31, 2024 | 16.81M |
| December 31, 2023 | 12.75M |
| September 30, 2023 | 13.87M |
| June 30, 2023 | 8.911M |
| March 31, 2023 | 8.738M |
| December 31, 2022 | 7.626M |
| September 30, 2022 | 8.151M |
| June 30, 2022 | 6.418M |
| March 31, 2022 | 5.684M |
| December 31, 2021 | 7.618M |
| September 30, 2021 | 6.532M |
| June 30, 2021 | 7.252M |
| March 31, 2021 | 7.589M |
| December 31, 2020 | 10.16M |
| September 30, 2020 | 5.603M |
| June 30, 2020 | 6.079M |
| Date | Value |
|---|---|
| March 31, 2020 | 13.20M |
| December 31, 2019 | 8.723M |
| September 30, 2019 | 9.575M |
| June 30, 2019 | 10.46M |
| March 31, 2019 | 10.02M |
| December 31, 2018 | 9.857M |
| September 30, 2018 | 9.509M |
| June 30, 2018 | 9.268M |
| March 31, 2018 | 8.539M |
| December 31, 2017 | 6.434M |
| September 30, 2017 | 4.966M |
| June 30, 2017 | 4.164M |
| March 31, 2017 | 2.948M |
| December 31, 2016 | 3.488M |
| September 30, 2016 | 2.142M |
| June 30, 2016 | 1.29M |
| March 31, 2016 | 7.875M |
| December 31, 2015 | 7.158M |
| September 30, 2015 | 7.33M |
| June 30, 2015 | 7.734M |
| March 31, 2015 | 6.042M |
| December 31, 2014 | 4.932M |
| September 30, 2014 | 5.402M |
| June 30, 2014 | 4.820M |
| March 31, 2014 | 4.281M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Gilead Sciences, Inc. | 1.69B |
| Insmed, Inc. | 210.03M |
| United Therapeutics Corp. | 146.30M |
| Vertex Pharmaceuticals, Inc. | 993.80M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |